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ABSTRACT
Active pharmaceutical substances require an International Nonproprietary Name (INN) assigned by the
World Health Organization (WHO) to obtain market authorization as a medicinal product. INNs are
selected to represent a unique, generic name for a drug enabling unambiguous identiﬁcation by
stakeholders worldwide. INNs may be requested after initiating clinical development of an investigational
drug. Pharmaceutical classes are indicated by a common stem or sufﬁx. Currently, INNs for monoclonal
antibody-based drugs are recognized by the sufﬁx, -mab, preceded by a source inﬁx such as -xi-
(chimeric), -zu- (humanized) or -u- (human) designating the species from which the antibody was derived.
However, many technological advances have made it increasingly difﬁcult to accurately capture an
antibody’s source in its name. In 2014, the WHO and the United States Adopted Names (USAN) Council
approached this challenge by implementing changes to antibody source inﬁx deﬁnitions. Unfortunately,
gaps and ambiguities in the deﬁnitions and procedures resulted in inconsistent source category
assignments and widespread confusion. The Antibody Society, extensively supported by academic and
industry scientists, voiced concerns leading to constructive dialog during scheduled consultations with
WHO and USAN Council representatives. In June 2017, the WHO announced that use of the source inﬁx
will be discontinued for new antibody INNs effective immediately. We fully support this change as it better
aligns antibody INNs with current and foreseeable future innovations in antibody therapeutics. Here we
review the changes implemented. Additionally, we analyzed antibody INNs recently assigned under the
previous 2014 deﬁnitions and provide recommendations for further alignment.
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Introduction
“The best laid schemes o’ mice an’ men / Gang aft a-gley.” This
line of the well-known poem by Robert Burns1 eloquently
expresses the notion that things, even though carefully planned,
can often go wrong. In fact, this is what happened with well-
intended changes to the deﬁnitions used to assign the source
inﬁx (substem) for (generic) INN and USAN for antibody ther-
apeutics (see appendix for details). Speciﬁc concerns with
respect to the changes in the INN and USAN source designa-
tions have previously been discussed in detail elsewhere.2
Contemporary INNs lack transparency and consistency in
source inﬁx designations
The WHO and the USAN Council are not, to our knowledge,
planning to change recommended INNs previously issued
under the 2014 deﬁnitions. Therefore, we considered it impor-
tant to reinvestigate nomenclature practices for contemporary
INNs to identify and highlight shortcomings. We systematically
analyzed all INN for antibody therapeutics as they occur in the
most recent 2017 INNs Recommended List (RL77).3 The
results summarized in Table 1 reinforce our previous
concerns,2,4 and show that multiple inconsistencies occur for
antibodies with a chimeric or humanized source designation.
The four antibodies at the top of Table 1 all received a chimeric
(-xi-) or mixed (-xizu-) INN designation; the latter referring to
antibodies containing both a chimeric and a humanized heavy
or light chain. Dinutuximab beta is based on mouse variable
(V) domains fused to human constant (C) domains and there-
fore represents a genuine chimeric antibody generated via clas-
sic domain exchange.5 The other three antibodies categorized
as chimeras or mixed by their INNs, in contrast, were human-
ized using common methods.6-8 The chimeric designation of
andecaliximab highlights the drawbacks of using linear
sequence homology to categorize therapeutic antibodies by
source. For this antibody, a humanization procedure was used
that employs non-contiguous human framework regions (FRs)
aimed at minimizing T cell epitope content and reducing
immunogenicity risks.6,9 Next, rozanolixizumab represents the
INN with the least transparent source designation in RL77.
Despite its mixed source -xizu- designation and its annotation
as a “humanized and chimeric antibody,” the INN description
(i.e. additional information published by WHO),3 only shows
alignments of rozanolixizumab’s variable region sequences
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with Homo sapiens VH and VL reference genes with 86.5 and
76% homology, respectively (ref. 3 and Table 1). The IMGT/
DomainGapAlign searches saved for rozanolixizumab in
IMGT/mAb-DB10,11 also exclusively show the same human ref-
erence genes. So if the reference genes are human, then what is
the mixed source designation based on? Notably, rerunning the
IMGT reference gene database search as described in Methods
reveals that the light chain aligns more closely to macaque VL
genes with 7 Macaca mulatta reference alleles showing slightly
greater homology compared with the ﬁrst human VL hit (i.e.,
77–79% versus 76%, respectively; Table 2). Differences are sub-
tle, however, with rozanolixizumab VL showing 20 amino acid
changes in FR1- FR3 compared with both the top macaque
(i.e., IGKV1-1301 with 9 changes in FR1-3 and 11 in comple-
mentary-determining region (CDR)1–2) as well as the top
human (i.e., IGKV1–1701 with 8 changes in FR1–3 and 12 in
CDR1–2) reference allele hit in IMGT/DomainGapAlign. The
lower score for the human references allele can therefore be
attributed to a slightly greater dissimilarity of the CDR-L3
which, in fact, was grafted from the parental rat antibody dur-
ing humanization. Rozanolixizumab’s light chain, therefore,
reasonably should also have obtained a humanized source des-
ignation. Unexpectedly, it was assigned a mixed chimeric stem
instead which, in addition, is at odds with the documentation
provided by WHO about this particular INN.3 Multiple incon-
sistencies were also found for 10 of 14 antibodies with a
humanized INN designation upon redoing the IMGT/Domain-
GapAlign search (Table 2). In most cases, we obtained a
macaque reference gene as a top hit instead of the human gene
listed, although in 2 instances mouse reference genes were also
found.
There may be multiple explanations for the observed incon-
sistencies. First, there is no precise deﬁnition of what consti-
tutes “closer to human than to other species” in the reference
database search. Presumably, an INN examiner may determine
that a sequence aligns most closely to a human reference gene
even if non-human genes score slightly higher but the observed
homology is of similar magnitude (see appendix). This may be
of particular relevance if the result is affected by differential
alignment in CDR sequences. Macaque reference genes, for
example, may obtain a higher IMGT/DomainGapAlign score
through a closer homology with rodent CDRs or, due to an arti-
fact of the local alignment algorithm by having no identity or
similarity in the V gene termini (CDR3 and FR3), even though
alignment for the corresponding region in the human counter-
part is better.2 However, such subjectivity in assigning an
appropriate source category is highly problematic as discussed
above (Table 1). Second, results may vary over time as the com-
position of the IMGT gene reference database changes due to
additional genome sequences becoming available in which spe-
ciﬁcally the addition of macaque germline reference genes with
high allelic variation is of concern.2 Finally, inconsistencies will
occur when an INN for an antibody contained in a novel com-
pound was issued before the 2014 change in source deﬁnitions.
This is exempliﬁed by gemtuzumab ozogamicin. The INN for
the antibody portion of this antibody-drug conjugate (ADC)
was issued in 2001 without its sequence being made available.12
In fact, sequences have only been systematically disclosed in
the INN description since RL57 released in 2007.13 The subjec-
tivity and time-dependence of antibody INNs creates undesired
uncertainties with respect to predicting and interpreting INN
source categories.
As noted, the USAN deﬁnition differs from INN by using an
85% sequence cut-off deﬁnition for distinguishing chimeric
from humanized antibodies (appendix). When using the USAN
deﬁnition, only 8 of 19 antibody heavy chains and 9 of 19 light
chains would have obtained a humanized designation. Interest-
ingly, rozanolixizumab’s nomenclature would be consistent
with USAN’s deﬁnitions for a mixed source antibody. This anti-
body however has not been assigned a USAN,14 so the pre-exis-
tence of a USAN cannot explain the discrepancies described.
Examining the 8 human antibodies in RL77, we observe
no discrepancies, which is as expected due to the absence of
a deﬁnition (Fig. 1; appendix). Ironically, the only antibody
in RL77 derived from an immune response in a human
individual (i.e., the second Fab in the bispeciﬁc DVD lutiki-
zumab was cloned from a patient with auto-immune dis-
ease15,16) did not earn the antibody a (mixed) human INN
Table 2. Inconsistencies in source inﬁx designations analyzed for antibodies from RL77.
Heavy chain Light chain
Antibody INN
Top hit species
(searched May 2017)a
Homology to top
hit species (%)
If different, homology to
closest human (%)
Top hit species
(searched May 2017) a
Homology to top
hit species (%)
If different, homology to
closest human (%)
andecaliximab Mus musculus 82.5 71.1 Macaca mulatta 81.1 80
rozanolixizumab Homo sapiens 86.5 Macaca mulatta 79.0b 76
camrelizumab Homo sapiens 90.8 Macaca mulatta 87.6 87.4
crizanlizumab Homo sapiens 81.6 Macaca mulatta 87.1 86.9
daclizumab beta Macaca fascicularis 83.7 82.7 Homo sapiens 84.0
dezamizumab Homo sapiens 85.7 Macaca mulatta 86.3 85.3
gemtuzumab ozogamicin Mus musculus 77.1 72.9 Homo sapiens 81.9
lutikizumab Fab 1- Homo sapiens 81.6 Macaca mulatta 82.4 82.1
Fab 2- Homo sapiens 88.8 Macaca mulatta 94.4 92.6
rosmantuzumab Homo sapiens 84.5 Macaca mulatta 83.9 83.8
sacituzumab Homo sapiens 85.7 Mus musculus 83.2 82.2
trastuzumab duocarmazine Homo sapiens 81.6 Macaca mulatta 86.5 86.3
vunakizumab Macaca fascicularis 84.7 82.7 Mus musculus 81.9 80
aResults that differ from the closest reference gene or allele species shown in RL77 and as referenced in the IMGT/mAb-DB INN database are shown in red. New search
was performed as stated in Methods. The homology to the closest human reference gene or allele is provided.
bSearch provides 7 Macaca mulatta reference alleles that have greater homology than the Homo sapiens reference allele.
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designation. The wide range of technologies used to access
human sequences for generating therapeutic antibodies is
noteworthy. These technologies include mRNA-display,
multiple distinct phage-display and several distinct trans-
genic mice platforms (Table 1), and exemplify that thera-
peutic antibodies can have many origins (Fig. 2). Additional
similar technologies, often used in conjunction, are being
used to ﬁll early pharmaceutical development pipelines.
INNs requests for such antibodies can be expected for sub-
mission in the near future.
In summary, therapeutic antibody INNs as well as the
accompanying description published in the INN Recom-
mended List RL77 lack consistency and transparency in source
inﬁx designations for chimeric and humanized antibodies.
Fixing the source inﬁx
On behalf of its members and scientists who signed an online
petition, The Antibody Society engaged in discussions with the
WHO INN expert group and representatives from the USAN
Council and Food and Drug Administration (FDA) during the
62nd open consultation on INN for Pharmaceutic Substances in
April 2016 and an ad hoc meeting on Biologicals in September
2016.4,17 The Antibody Society, in collaboration with key stake-
holders, developed proposals to revise the INN system to pro-
vide scientiﬁcally sound, distinguishing names for therapeutic
antibodies in current and future development.
Two potential solutions were discussed. The ﬁrst was to
drop the use of the source inﬁx and sequence alignments to cat-
egorize antibodies altogether. The second was to improve the
current system, for example by generating a new expanded
‘engineered’ source inﬁx which should take current and future
developments in antibody generation technologies into
account. Although no general consensus was reached at the
workshop, dropping the source inﬁx was a favored solution.17
Removing the source inﬁx would, as a side effect, create more
ﬂexibility in the assignment of INNs. This is important as it
was noted that, due the large increase in applications for biolog-
icals, it is becoming increasingly difﬁcult to design new distin-
guishable INNs.17
After considering all options, the WHO announced it was
decided at the 64th consultation on INN for Pharmaceutical
Substances held April 4–7, 2017 in Geneva, Switzerland that
they will discontinue the use of the source inﬁx in antibody
INNs.18 The make-up of previous and new antibody INN
nomenclature rules are summarized in Fig. 3.
Antibody INNs: Beyond the source inﬁx
The target inﬁx (substem A) is determined by the target (mole-
cule, cell or organ) class.17 The information provided by a sin-
gle syllable can only in very general terms describe the
intended target for an antibody, especially as an antibody’s tar-
get molecule is often expressed on multiple cells in multiple
Figure 1. The INN source substem for therapeutic antibodies. Antibody INNs issued until June 2017 (with the exception of the ﬁrst antibody INN muromonab-CD3) con-
tain a source inﬁx designating the species. The antibody’s origin determined the source inﬁx until 2014. For antibody INN issued between 2014 and early 2017, the source
inﬁx was determined using a sequence alignment procedure, which led to inconsistent source inﬁx designations for chimeric and humanized antibodies. No deﬁnitions to
determine a human source existed (see appendix).
Figure 2. An expanding toolbox for the generation of therapeutic antibodies that
meet modern biopharmaceutical requirements. Therapeutic antibodies can be
generated in many ways and capturing an antibody’s source in a single syllable is
therefore no longer possible.
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organs. In addition, since therapeutic antibodies may be devel-
oped for additional or different indications after the INN has
been assigned, the INN is not always consistent with the disease
target. For example, rituximab includes the -tu- target inﬁx
consistent with its oncology but not inﬂammatory disease indi-
cations. Discontinuation of the target inﬁx was discussed as a
means of generating further ﬂexibility in generating clearly dis-
tinct INNs for antibodies.17 Overall, arguments for discontinu-
ing the target inﬁx are less compelling and urgent than for the
source inﬁx. Optimizing or potentially discontinuing the use of
the target inﬁx should therefore be addressed in future
discussions.
Antibody INNs may sometimes contain a second word17 that is
added to conjugates of antibodies with other molecules such as a
toxin, chelator or chemical (e.g., the ADCs shown in Table 1). If
the antibody also contains a radiolabel, the isotope is listed at the
start of the INN (i.e., name of the isotope, element and isotope
number followed by the generic antibody name). The INN does
not contain a speciﬁc designation to specify that a substance is a
fusion protein, although this is currently under discussion. Anti-
bodies with identical amino acid sequence (or containing minor
processing differences) but distinct glycosylation are provided with
a new INN containing a Greek letter as a secondword, e.g., daclizu-
mab beta (Table 1). This antibody was generated from a new cell
line using a distinct manufacturing process generating carbohy-
drate species that are more homogenously fucosylated than the
originator product Zenapax(daclizumab), thereby reducing IgG
Fc receptor IIIa binding and antibody-dependent cell-mediated
cytotoxicity.17,19 Finally, the second word ‘pegol’ indicates PEGy-
lated antibodies, e.g., certolizumab pegol.
The stem -mab has been used in INNs for all antibody-con-
taining substances. However, the intention to introduce INNs
for antibody-fusion proteins consisting of a single word con-
taining the stem -fusp has been discussed. Although general
consensus was not reached, it was decided to test the -fusp stem
on 2 outstanding requests.17
For recombinantly expressed polyclonal antibodies (also
known as designer polyclonals), each antibody in the mixture
will usually require a separate INN. However, this may not be
appropriate for recombinant polyclonal antibodies manufac-
tured using single batch production strategies. In a USAN, the
sufﬁx -pab20 may then be used, such as in rozrolimupab, which
comprised 25 different recombinant anti-rhesus D antibodies.21
A sufﬁx for such recombinant polyclonal drug substances is not
available for INNs, but in view of future development should
likely be considered.
Beyond INN
In some cases, a preﬁx may be added to speciﬁc antibody prod-
ucts to avoid medication errors and facilitate pharmacovigi-
lance.22 The FDA, for example, included the preﬁx ado- to the
ADC ado-trastuzumab emtansine (Kadcyla) to distinguish it
from the non-drug conjugated trastuzumab. This is to mitigate
the risk that the name is misread or mislabeled and to avoid
administration of the wrong drug, which could lead to serious
adverse events.22,23 Further use of preﬁxes for speciﬁc drugs
should be considered as additional conjugates with the same
antibody are being developed (e.g., trastuzumab duocarmazine
(Table 1)).
The addition of a Biological Qualifyer (BQ) to the INN has
also been extensively discussed by WHO, the USAN Council
and the FDA. It is envisioned that each biologic product,
including originator products, related biologic products and
biosimilars, would obtain an additional sufﬁx. The WHO pro-
posed the use of a random 4-letter code supplemented with a
2-digit checksum as a BQ, which should be used in conjunction
with the INN to uniquely identify an antibody product to pro-
mote world-wide pharmacovigilance.24 The BQ would further-
more help the accurate identiﬁcation of antibody products by
health care providers and patients and avoid unintended substi-
tution. Although the BQ is considered an important issue,
details are still being worked out while a pilot program with
regulators is being discussed.17 The FDA recently released an
Industry Guidance document proposing the use of a 4-letter
sufﬁx as a biologic qualiﬁer.22,25 Three biosimilar antibody
products have so far been issued such a sufﬁx, these include
adolimumab-atto (Amjevita), inﬂiximab-dyyb (Inﬂectra) and
inﬂiximab-abda (Renﬂexis). A further alignment between regu-
latory authorities will be essential to achieve consistency and
maximal leverage of the approach.
Future perspectives
The WHO decision to discontinue the use of the source inﬁx in
antibody INNs is an important step forward and addresses the
Figure 3. Antibody INN ABC. The general naming scheme for antibody INN before
2017 is compared with the new system. Prior to 2017, the random preﬁx was fol-
lowed by a target inﬁx (substem A) of which -t(u)- for tumor, -l(i)- for immunomod-
ulatory, -c(i)- for cardiovascular, and -k(i)- for interleukin represented major classes.
The source inﬁx (substem B) indicated the source of which -xi- for chimeric, -zu-
for humanized and -u- for human represented major classes (see the Bioreview
(2014)27 for complete listing). In the new scheme, the source inﬁx designating the
species has been discontinued as recommended by the INN expert group during
the 64th INN Consultation.18, 60 To avoid confusion with earlier schemes, -ta- now
designates tumor antigen. Furthermore, -ba- designates bacterial, -ami- serum
amyloid protein(SAP)/amyloidosis, -ci- cardiovascular, -fung- fungal, -gros- skeletal
muscle mass-related growth factors and receptors, -ki- interleukin, -li- immunomo-
dulating, -ne- neural, -os- bone, -toxa- toxin and -vi- viral. The source inﬁx -vet- for
veterinary use antibodies is retained and added to the ‘target’ inﬁx list. The sufﬁx
-mab represents the common stem for antibody therapeutics.18
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concerns and objections raised by The Antibody Society on
behalf of many academic and industry scientists in the antibody
ﬁeld.2 The new naming scheme accepted at the 64th Consulta-
tion has swiftly been implemented by WHO as we have learned
that it has already been adopted in INNs currently proposed to
applicants. Since the shortcomings of the 2014 source deﬁnitions
extend to the Additional Information provided in the INN
description (e.g., as in RL77 discussed here), we urge the WHO
INN expert group to completely retire the use of categorizing
therapeutic antibodies for source by using sequence alignments.
The WHO announced that the INN description is envisioned to
contain more extensive information on the antibody’s origin
and that information regarding the species on which the anti-
body’s sequence is based will continue to be included in the def-
inition for antibody INN.18 We fully support the inclusion of
more precise information of the antibody’s origin and genera-
tion in the INN description. However, continuing the practice
of describing antibodies as chimeric, humanized and human in
the INN description on the basis of ambiguous and inconsistent
deﬁnitions, in spite of discontinuing the source inﬁx in the
actual INN, would be a very poor solution that should be recon-
sidered. Going forward, we request the WHO to consider omit-
ting the source inﬁx from antibody INNs currently under
discussion (e.g., INNs in the 2016 Proposed List PL116),26 as
well as to review anomalies in previously assigned INNs. Most
importantly, discontinuing the use of sequence alignments to
determine an antibody’s origin in the INN description would
allow the most complete resolution of the issue.
Methods
Database analysis of antibody INNs
The antibody names in the Recommended INN: List 773 were
examined. The assigned VH and VL reference genes or alleles
were searched in IMGT/mAb-DB34,35 using the INN as “Gen-
eral Query” and examined in the IMGT/2D structure-DB card
for the INNs using the link provided in the Table on the respec-
tive IMGT/mAb-DB result page. The saved IMGT/DomainGa-
pAlign results were accessed using the links provided at the
bottom in the box designating the V-domain of the heavy and
light chain, respectively. This link provides the top 5 “Closest
reference gene and allele(s) from the IMGT V domain direc-
tory.” The top hit corresponds to the reference gene and species
listed in RL77.3 The top hit and percentage homology are noted
in Table 1 in this manuscript. Next, a new IMGT/DomainGap-
Align search against the current databased was performed by
scrolling to the top of the page and executing “Align and IMGT
-gap my sequence(s).” Searches were performed against the
database available in weeks 17 and 18 (2017). Antibodies for
which a different top hit relative to the species stated in RL77
was found are highlighted in red in Table 1 and further details
are provided in Table 2. Patent applications and patents can be
accessed via https://worldwide.espacenet.com/.
Web-based materials
All links and searches in this manuscript were checked for
accuracy at the time of writing. Since links may become
inoperative or linked information may be retired or changed,
relevant copies are being kept on ﬁle at The Antibody Society
and may be accessed in the “member’s only” area on The Anti-
body Society’s website (http://www.antibodysociety.org) or
directly requested from the authors.
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Appendix. The INN source inﬁx explained
The WHO provides International Nonproprietary Names
(INNs) to therapeutic antibodies.27,28 A complete and current
list of INNs for therapeutic antibodies approved or under regu-
latory review in the US and EU can be found on The Antibody
Society’s website.29 The INN is composed of a random, unique
preﬁx of several syllables, a ﬁrst inﬁx (substem A), which is
deﬁned by the target, and second inﬁx (substem B), which is
deﬁned by the source, and the sufﬁx (stem) -mab.27 The source
inﬁxes were developed during 1991–1993,30 and, although deﬁ-
nitions were reﬁned over the years, the delineations between
the various categories remained the same until 2014 (see
Fig. 1).28,31 The most common inﬁx indicating the source
are:-o- for all mouse sequence-derived antibodies, -u- for all
human sequence-derived antibodies, -xi- for antibodies in
which the mouse-derived variable region were combined with a
human constant region (variable domain exchange) and -zu-
for antibodies in which the mouse-derived complementarity
determining regions were combined with a human variable
region framework and human constant region. The origin of
the antibody or the technology used to generate the therapeutic
antibody deﬁned the inﬁx unequivocally in the early years.
Progress in antibody technologies, however, has increasingly
blurred boundaries between the various source categories,
resulting in an antibody landscape consisting of a continuum
of sequences. Through these advances, therapeutic antibodies
with the characteristics that are required for modern biophar-
maceuticals can be generated with sequences derived from a
myriad of in vitro and in vivo technologies, distinct animal spe-
cies and transgenic animals or even fully synthetic sources.
These further changes include the introduction of deﬁned point
mutations for optimizing binding, the mitigation of manufac-
turability and developability liabilities (such as replacing amino
acids prone to undesired post-translation modiﬁcations) and
the removal of T-cell epitopes (to lower the antibody’s immu-
nogenicity risk proﬁle). Finally, many technologies to optimize
the therapeutic antibodies’ functionality are being applied (see
Fig. 2). The existing nomenclature system, therefore, was
becoming outdated, which was a challenge that the WHO INN
expert group attempted to address by developing novel inﬁx
deﬁnitions.
The WHO updated deﬁnitions for the source inﬁx released in
201427 handled the distinction between chimeric antibodies and
humanized antibodies in a novel and unprecedented way. The
new deﬁnitions included a sequence alignment procedure
whereby the source inﬁxes were now deﬁned by the sequence of
the end product and not their factual origin. In 2015, the INN
expert group clariﬁed that alignments need to be performed by
using the IMGT/DomainGapAlign tool.10,11 The -xi- or -zu- inﬁx
is determined via the alignment of the amino acid sequence
encoded by the V-gene only (i.e., FR1 through FR3 for the heavy
chain (VH) and FR1 through CDR3 for the light chain (VL)) to
the IMGT sequence reference database. The top hit(s) determine
the closest species. For a humanized antibody, the ﬁrst hit for
“Closest reference gene and allele(s) from the IMGT V domain” in
the DomainGapAlign result therefore should be a human
sequence. A ﬁrst hit on the list with any other species designates a
chimeric antibody. Although this sounds easy in theory, execution
is less straightforward. In cases where multiple sequences have
similar scores, such as for example where ‘human’ is second or
third to ‘macaque’ with only small deviations in the percentage
homology score, the designation ‘humanized’ may still be pro-
vided by WHO. However, since precise cut-offs have not been
disclosed, it is no longer possible for stakeholders to unambigu-
ously predict the source designation that will be provided in the
INN. The procedure therefore lacks transparency and consistency.
Remarkably, no deﬁnitions for determining the human -u- source
inﬁx have been provided, and its designation therefore still hinges
on the origin of the antibody’s variable domains in a human
sequence library of some sort, and relies on information provided
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by the INNs applicant. This creates a necessity for an arbitrary
deﬁnition regarding whether an antibody with a fully human
sequence derived from 1) a library of natural genes, 2) a library of
synthetic genes, 3) from transgenic animals, or 4) from human
patients would automatically receive the -u- inﬁx, and potentially
blurs the boundary between the -u- and -zu- inﬁx.
Although INNs are used world-wide, several countries use a
separate system of non-proprietary names, one example of
which is the United States Adapted Names (USAN). The
USAN council is administered by the American Medical Asso-
ciation (AMA), and includes members of several agencies, e.g.,
the Food and Drug Administration (FDA). Interestingly, the
post-2014 assignment of source inﬁxes has also generated
debate between the INN expert group and the USAN Council.
In contrast to the INN top hit procedure explained above, the
source designation for a USAN is deﬁned by an 85% sequence
cut-off (with C85% human sequence content designating a
humanized antibody and a <85% content a chimeric).32,33 This
discrepancy has further confused the ﬁeld.2 During the 62nd
open consultation on INN, the FDA and INN expert group
representatives acknowledged the difference and indicated that
harmonization is essential because therapeutic antibodies in
development may have either an INN or a USAN and about
half have both.4 We note that all USAN for therapeutic anti-
bodies issued in 2017 thus far are also registered with INNs. In
contrast, of the 27 INNs published in 2017, only 9 also carry a
USAN.3,32
The ﬂaws in determining “humanness” of antibody sequen-
ces by alignment approaches were analyzed and debated by us
and others elsewhere.2 Overall, the notion that an antibody’s
origin can be captured in a single syllable has lost its validity
due to the increasing complexity of the antibody landscape
(Fig. 2). Moreover, the once useful information that was carried
in this one syllable can become outright misleading. The cut-
off value of a USAN according to human sequence content at
precisely 85% is highly questionable, as is an INN assigned
according to the top homology hit being a macaque or almost
identical human sequence. The source designation in antibody
INNs therefore became a highly disputed issue, and its resolu-
tion was awaiting an urgent deployment.
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